Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ratio exploration of prolonged-release naloxone with sustained-release morphine in moderate to severe cancer pain with opioid-induced constipation
CTR20252737Phase 2Active
- Sponsor
- Chengdu Easton Biopharmaceuticals Co., Ltd.
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naloxone, morphine in cancer pain, opioid-induced constipation (OIC), sponsored by Chengdu Easton Biopharmaceuticals Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
naloxonemorphine
03
Conditions
cancer painopioid-induced constipation (OIC)
Beyond the preview
Go deeper on CTR20252737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252737.